Adjuvant treatment for phenylketonuria (PKU)
Lindegren ML, Krishnaswami S, Fonnesbeck C, Reimschisel T, Fisher J, Jackson K, Shields T, Sathe NA, McPheeters ML

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
We systematically reviewed evidence on adjuvant treatment of phenylketonuria (PKU) and evidence for a target phenylalanine (Phe) level to minimize cognitive impairment.

Authors' conclusions
The strength of the evidence is moderate for a threshold effect of a Phe level of 400 ìmol/L associated with IQ <85. Evidence on the association of Phe and measures of executive function is insufficient. The use of adjuvant therapy in PKU is novel; the strength of the evidence is currently moderate for short-term effects on reducing Phe in a subset of initially responsive individuals and low for longer term effects on cognition.

Final publication URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Phenylketonuriass; Adjuvants, Pharmaceutical

Language Published
English

Country of organisation
United States

English summary
An English language summary is available.

Address for correspondence
AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov

AccessionNumber
32013000184

Date abstract record published
20/03/2013